Balancing Between Concentration and Volume when Developing Patient-Centric Biologics

Summary:When developing patient-centric products for biologics, different doses, expressed by different combinations of volume/concentration may require different delivery devices. As a result, it takes a great deal of time and effort in planning and coordinating the formulation and device activities. In this podcast, Pharma and Drug Delivery executives from Nanoform, Pfizer, GSK, Takeda and Kymanox discuss how they facilitate partnerships between drug product development, device engineering and clinical study teams to determine how to balance concentration and volume and develop optimal devices for delivery and commercialization. Specifically:Impact on increasing concentration of drugs on deliverabilityTechnical feasibility of manufacturing larger volume devicesPatient tolerability and human factors that impact patient adherenceThis panel discussion was recorded at the October 2024 PODD: Partnership Opportunities in Drug Delivery conference. For more information, go to Drug-Delivery.org.